Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2017

01-10-2017 | Erratum

Erratum to: Pro-apoptotic effect of Δ2-TGZ in “claudin-1-low” triple-negative breast cancer cells: involvement of claudin-1

Authors: Marine Geoffroy, Alexandra Kleinclauss, Stéphanie Grandemange, Sébastien Hupont, Michel Boisbrun, Stéphane Flament, Isabelle Grillier-Vuissoz, Sandra Kuntz

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Login to get access

Excerpt

In the original publication of the article, the given and family names of the authors were swapped. The corrected author group is given in this erratum. The original article was corrected. …
Metadata
Title
Erratum to: Pro-apoptotic effect of Δ2-TGZ in “claudin-1-low” triple-negative breast cancer cells: involvement of claudin-1
Authors
Marine Geoffroy
Alexandra Kleinclauss
Stéphanie Grandemange
Sébastien Hupont
Michel Boisbrun
Stéphane Flament
Isabelle Grillier-Vuissoz
Sandra Kuntz
Publication date
01-10-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4402-6

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue

Epidemiology

Patterns and predictors of first and subsequent recurrence in women with early breast cancer

Epidemiology

Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors

Epidemiology

Increasing utilization of regional nodal irradiation in elderly node-positive women and declining emphasis on demographic factors

Epidemiology

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

Clinical trial

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

Epidemiology

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits